Cargando…
Price-Cutting Trends in New Drugs after Listing in South Korea: The Effect of the Reimbursement Review Pathway on Price Reduction
This study aims to analyze the trends of post-listing price changes for new drugs listed from 2007, when the health technology assessment (HTA) was introduced in South Korea, until 2017. We analyzed 135 products that have undergone price cuts. These products were analyzed by their respective review...
Autores principales: | Kim, Sungju, Lee, Jong Hyuk |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7551345/ https://www.ncbi.nlm.nih.gov/pubmed/32722530 http://dx.doi.org/10.3390/healthcare8030233 |
Ejemplares similares
-
Pricing and Reimbursement Pathways of New Orphan Drugs in South Korea: A Longitudinal Comparison
por: Lee, Jong Hyuk
Publicado: (2021) -
Access to innovative drugs and the National Reimbursement Drug List in China: Changing dynamics and future trends in pricing and reimbursement
por: Macabeo, Bérengère, et al.
Publicado: (2023) -
Cell and gene therapy regulatory, pricing, and reimbursement framework: With a focus on South Korea and the EU
por: Lee, SungKyung, et al.
Publicado: (2023) -
The duration of cost-cutting effects of price-lists
por: Schilling, Ulf Martin
Publicado: (2010) -
Pricing and reimbursement of novel oncology drugs in Sweden
por: Haglund, Mattias, et al.
Publicado: (2014)